Physiological and morphological effects of alendronate on rabbit esophageal epithelium

被引:20
作者
Dobrucali, A
Tobey, NA
Awayda, MS
Argote, C
Abdulnour-Nakhoul, S
Shao, W
Orlando, RC
机构
[1] Tulane Univ, Sch Med, Dept Med, Sect Gastroenterol & Hepatol, New Orleans, LA 70112 USA
[2] Tulane Univ, Sch Med, Dept Physiol, New Orleans, LA 70112 USA
[3] Vet Affairs Med Ctr, New Orleans, LA 70112 USA
来源
AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY | 2002年 / 283卷 / 03期
关键词
biphosphonates; esophagitis; transepithelial ion transport; Ussing chamber; sodium channels;
D O I
10.1152/ajpgi.00014.2002
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Alendronate, an aminobisphosphonate, produces as a side effect a topical (pill induced) esophagitis. To gain insight into this phenomenon, we assessed the effects of luminal alendronate on both esophageal epithelial structure and function. Sections of rabbit esophageal epithelium were exposed to luminal alendronate at neutral or acidic pH while mounted in Ussing chambers to monitor transmural electrical potential difference (PD), short-circuit current (I-sc), and resistance (R). Morphological changes were sought by light microscopy in hematoxylin and eosin-stained sections. Impedance analysis was used for localization of alendronate-induced effects on ion transport. Luminal, but not serosal, alendronate (pH 6.9-7.2), increased PD and I-sc in a dose- and time-dependent manner, with little change in R and mild edema of surface cell layers. The changes in I-sc (and PD) were reversible with drug washout and could be prevented either by inhibition of Na, K-ATPase activity with serosal ouabain or by inhibition of apical Na channels with luminal acidification to pH 2.0 with HCl. An effect on apical Na channel activity was also supported by impedance analysis. Luminal alendronate at acidic pH was more damaging than either alendronate at neutral pH or acidic pH alone. These data suggest that alendronate stimulates net ion (Na) transport in esophageal epithelium by increasing apical membrane sodium channel activity and that this occurs with limited morphological change and no alteration in barrier function. Also alendronate is far more damaging at acidic than at neutral pH, suggesting its association with esophagitis requires gastric acid for expression. This expression may occur either by potentiation between the damaging effects of (refluxed) gastric acid and drug or by acid-induced conversion of the drug to a more toxic form.
引用
收藏
页码:G576 / G586
页数:11
相关论文
共 24 条
[1]  
Abraham SC, 1999, MODERN PATHOL, V12, P1152
[2]   Upper gastrointestinal tract safety profile of alendronate -: The Fracture Intervention Trial [J].
Bauer, DC ;
Black, D ;
Ensrud, K ;
Thompson, D ;
Hochberg, M ;
Nevitt, M ;
Musliner, T ;
Freedholm, D .
ARCHIVES OF INTERNAL MEDICINE, 2000, 160 (04) :517-525
[3]   Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures [J].
Black, DM ;
Cummings, SR ;
Karpf, DB ;
Cauley, JA ;
Thompson, DE ;
Nevitt, MC ;
Bauer, DC ;
Genant, HK ;
Haskell, WL ;
Marcus, R ;
Ott, SM ;
Torner, JC ;
Quandt, SA ;
Reiss, TF ;
Ensrud, KE .
LANCET, 1996, 348 (9041) :1535-1541
[4]  
Breuil V, 1999, REV RHUM, V66, P339
[5]   Esophagitis dissecans superficialis and alendronate: case report [J].
Cameron, RB .
GASTROINTESTINAL ENDOSCOPY, 1997, 46 (06) :562-563
[6]  
CIOSEK CP, 1993, J BIOL CHEM, V268, P24832
[7]   Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures - Results from the fracture intervention trial [J].
Cummings, SR ;
Black, DM ;
Thompson, DE ;
Applegate, WB ;
Barrett-Connor, E ;
Musliner, TA ;
Palermo, L ;
Prineas, R ;
Rubin, SM ;
Scott, JC ;
Vogt, T ;
Wallace, R ;
Yates, AJ ;
LaCroix, AZ .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1998, 280 (24) :2077-2082
[8]   The bisphosphonate tiludronate is a potent inhibitor of the osteoclast vacuolar H+-ATPase [J].
David, P ;
Nguyen, H ;
Barbier, A ;
Baron, R .
JOURNAL OF BONE AND MINERAL RESEARCH, 1996, 11 (10) :1498-1507
[9]   Esophagitis associated with the use of alendronate [J].
deGroen, PC ;
Lubbe, DF ;
Hirsch, LJ ;
Daifotis, A ;
Stephenson, W ;
Freedholm, D ;
PryorTillotson, S ;
Seleznick, MJ ;
Pinkas, H ;
Wang, KK .
NEW ENGLAND JOURNAL OF MEDICINE, 1996, 335 (14) :1016-1021
[10]   Prevention of bone loss with alendronate in postmenopausal women under 60 years of age [J].
Hosking, D ;
Chilvers, CED ;
Christiansen, C ;
Ravn, P ;
Wasnich, R ;
Ross, P ;
McClung, M ;
Balske, A ;
Thompson, D ;
Daley, M ;
Yates, AJ .
NEW ENGLAND JOURNAL OF MEDICINE, 1998, 338 (08) :485-492